Brief: Hexima Announces Results Of Phase II Study Of Pezadeftide For Treatment Of Onychomycosis

Hexima

11/07/2022 02:11

July 11 (Reuters) - Hexima Ltd  HXL.AX :
    * HEXIMA LTD - RESULTS OF ITS PHASE II CLINICAL STUDY OF
PEZADEFTIDE (HXP124) FOR TREATMENT OF ONYCHOMYCOSIS
    * HEXIMA LTD - PEZADEFTIDE WAS WELL-TOLERATED AND SAFE
    * HEXIMA LTD - HAS INITIATED A PROCESS OF SEEKING
EXPRESSIONS OF
INTEREST IN PURCHASE OR LONGER TERM LEASE OF FACILITY
    * HEXIMA - DOES NOT BELIEVE DATA SUPPORT CO'S GOAL OF
DEVELOPING
SAFE, MORE EFFECTIVE, CONVENIENT TOPICAL THERAPY WITH SHORTER
COURSE OF TREATMENT
    * HEXIMA LTD - INTENDS TO WIND DOWN ITS DEVELOPMENT PROGRAM
OF
PEZADEFTIDE FOR TREATMENT OF ONYCHOMYCOSIS IN AN ORDERLY FASHION
    * HEXIMA - INITIATED PROCESS OF EXPLORING STRATEGIC OPTIONS
FOR CO
SEEKING TO SECURE VALUE FOR CO'S INTELLECTUAL PROPERTY AND
RESIDUAL CASH RESOURCES
    * HEXIMA LTD - DISCUSSIONS ARE VERY PRELIMINARY AND
CONTEMPLATED
TRANSACTION OR TRANSACTIONS MAY OR MAY NOT OCCUR
    * HEXIMA LTD - INITIATED ORDERLY PROCESS OF WINDING UP
VARIOUS
MANUFACTURING AND NON- CLINICAL DEVELOPMENT ACTIVITES IN A COST
EFFICIENT MANNER
    * HEXIMA LTD - EXPENSES ASSOCIATED WITH NON-ESSENTIAL
EMPLOYEES
AND CONTRACTORS ARE BEING MANAGED IN A COST EFFECTIVE AND
ORDERLY MANNER

Source text for Eikon:  ID:nASX1WhYXG 
Further company coverage:  HXL.AX 

 ((Reuters.Briefs@thomsonreuters.com;))